Supercharging
The Immune System
NKore is utilizing a natural, proprietary approach to “Supercharging” allogeneic Natural Killer Cells to deploy a new era in immunotherapeutic medicine for the treatment of cancer and other immune-related diseases in patients of all ages. At NKore, we put patients first!
NK101
Backed by Over 35 Years of
Research, Our Allogeneic sNK
Therapy, NK101, Offers a Non-Toxic
Approach to Cancer Healthcare
Patient Stories
From Adults to Pediatrics,
NK101 is Showing Promise in
Both Solid and Blood Cancers
Without the Harsh Side Effects.
Path to Market
Focused on FDA Approval
in the United States, NKore
is Positioned to Begin Human
Trials in 2025
NKore BioTherapeutics is a cellular-based biotherapeutics company focused on the early detection, prevention, and treatment of cancer. Our technology is based on a proprietary method of activating natural killer (NK) cells, creating Supercharged Natural Killer (sNK) cells used as a novel oncology immunotherapy platform. Our proprietary activation method enhances NK cells’ overall effectiveness, making them significantly more potent (i.e., they are more cytotoxic to the cancer cells), while reducing the likelihood of tumor regeneration and metastasis.
The technology was developed by Dr. Anahid Jewett, the Company’s co-founder and Chief Scientific Advisor. Based on positive preclinical results, we believe that Dr. Jewett’s 35-plus years of researching NK cell function has resulted in the development of a novel and effective cancer immunotherapy. NKore’s current focus is to translate and replicate the positive preclinical results into human clinical trials and achieve marketing approval. Patients are actively receiving treatments and showing early signs of a positive response with no negative side effects currently reported.
News & Events
Latest & Greatest
Carlsbad, CA – October 2025 — NKore BioTherapeutics and its Co-Founder & Chief Communications Officer, Tracy Ryan, have been recognized with the Impact Award at the prestigious Global Capital Network (GCN) Investor Conference for their groundbreaking work in developing non-toxic, Natural Killer (NK) cell therapies aimed at treating terminal and incurable cancers. The award celebrates companies that are creating measurable, life-changing impact across industries — and few stories embody that mission more powerfully than NKore’s. Founded out of a mother’s determination to save her child, NKore’s journey began when Tracy Ryan’s daughter, Sophie, was diagnosed with a rare and aggressive brain tumor as a baby. Refusing to accept traditional limits, Ryan partnered with scientists and clinicians to pioneer a revolutionary approach to cancer treatment — one that harnesses the body’s own immune system through supercharged NK cells. Today, Sophie — now Patient #2 in NKore’s early human studies — represents both the inspiration and proof-of-concept behind the company’s technology. NKore’s proprietary NK101 cell platform has shown promising results in patients with aggressive, treatment-resistant cancers, providing new hope where conventional therapies have failed with Sophie's most recent scan showing crumbling in her incurable tumor. “Receiving the Impact Award is deeply personal for us,” said Tracy Ryan, following the ceremony. “NKore was born from love, desperation, and an unwavering belief that science could offer something better — not just for my daughter, but for every family told there are no options left. This award validates the impact we’re already making and the future we’re building.” The event, held in Carlsbad, CA, brought together investors, innovators, and thought leaders from across the biotech, healthcare, and technology sectors. NKore’s participation was marked not only by Ryan’s powerful on-stage pitch but also by her dynamic presence as Master of Ceremonies during the conference’s second half — a testament to her ability to connect scientific innovation with human purpose. Under Ryan’s leadership and alongside CEO Dr. Aaron U. Levy, NKore continues to advance its NK cell therapy pipeline toward clinical readiness, with a focus on solid tumors and other immune-related diseases. The company’s mission — “From Immune Anarchy to Precision Healing” — reflects its vision of restoring balance within the immune system through next-generation, off-the-shelf NK cell treatments. As NKore moves toward broader clinical trials and global partnerships, this Impact Award serves as both recognition of its achievements and motivation to continue pushing the boundaries of what’s possible in cancer immunotherapy.
We’re thrilled to announce that Tracy Ryan and her daughter Sophie Ryan will be the plenary keynote speakers at the PDA Southern California Chapter Cell Therapy Manufacturing: Emerging Trends event, taking place on Thursday, August 7, 2025 , at The Grand , Long Beach, CA . 🎤 About Our Speakers Tracy Ryan Co‑Founder and Chief Communications Officer of NKore BioTherapeutics, Tracy brings a compelling first‑hand perspective as a patient turned entrepreneur. Her keynote will illuminate the human impact and promise of cell therapy in transforming cancer care. Sophie Ryan Joining her mother on stage, Sophie brings a personal and deeply moving narrative of resilience, hope, and forward‑looking innovation—a powerful complement to Tracy’s story. Together, they offer a unique blend of scientific insight and lived experience , bridging the clinical and personal sides of cell therapy’s emergence. đź’ˇ Why You Should Attend Gain insider perspectives on emerging trends in cell therapy manufacturing , including scale‑up, regulatory pathways, and innovation in NK-based immunotherapies. Hear firsthand from leading voices in biotech entrepreneurship and patient‑driven innovation. Connect with industry professionals, researchers, and decision‑makers shaping the future of cell therapies. 🎟️ Get Your Tickets Don’t miss this opportunity to learn from two exceptional speakers at the forefront of cancer immunotherapy. Reserve your spot now here: Get Tickets for PDA SoCal — August 7, Long Beach
At this year’s Innate Killer Summit in San Diego , one of the most powerful and lasting impressions came from the work and wisdom of our beloved scientific founder, Dr. Anahid Jewett . Dr. Jewett, a pioneering immunologist and globally recognized NK cell expert, gave what would become some of her final public presentations—leaving an unforgettable mark on the international community of innate immune researchers and biotech leaders. Her talks, delivered with characteristic brilliance and humility, distilled decades of research into a clear, compelling vision: that natural killer cells are the future of cancer therapy , and that future is already within reach. Her presentations spanned the arc of her life’s work—from her early discoveries in NK cell cytotoxicity and tumor immune evasion, to the breakthrough techniques she developed to “supercharge” NK cells for clinical use. She walked the audience through the translational path from lab bench to bedside, showing data from patient studies that support the promise of non-toxic, precision immunotherapy for some of the most treatment-resistant cancers. But what made her presence at BPI’s Innate Killer Summit so deeply moving was not just the science—it was her spirit. Her commitment to patients, her fierce intellect, and her belief in the power of immune-based healing came through in every word. The response from the audience was overwhelming. Researchers, physicians, and investors alike approached our team throughout the week to express their gratitude for her work and their admiration for her clarity of vision. One attendee called her “the North Star of NK cell science.” We couldn’t agree more. As a company, NKore BioTherapeutics has been built on the foundation of Dr. Jewett’s groundbreaking research. And though she is no longer with us physically, she has left behind something far more powerful: a blueprint for innovation, a roadmap for clinical success, and an unshakable commitment to saving lives . We are proud to carry forward her legacy. We are advancing the very therapies she envisioned, treating patients who once had no options, and moving closer every day to an era where cancer can be treated effectively and gently—through the body’s own immune defenses. Thank you, Dr. Jewett, for everything. You’ve given the world more than it knows, and we will never stop building the future you helped us see.
Want To Learn More? Drop Us A Line!
We love hearing from patients and supporters who want to learn more.
Documentary Teaser Trailer
Saving Sophie: The Road to a Cure
In this 9-minute teaser to the poignant documentary "Saving Sophie: The Road to a Cure," you are invited into the heart-wrenching journey of the Ryan family, who faced the unimaginable when their daughter Sophie was diagnosed with a brain tumor at just 8½ months old. This film gives an inside look at their relentless fight for her life and the incredible resilience of a mother who, in the face of adversity, CoFounded NKore BioTherapeutics with world renowned research scientist, and UCLA professor and director of the tumor immunology board, Dr. Anahid Jewett. 
NKore is revolutionizing cancer treatment and offering hope to countless families. Witness the power of love, innovation, and determination in a story that will inspire and uplift, as the NKore team strives not only to save Sophie, but to transform the future of cancer care.
